361 related articles for article (PubMed ID: 30975353)
21. ANALYSIS OF CHANGES IN CHARACTERISTICS OF SEVERE RETINOPATHY OF PREMATURITY PATIENTS AFTER SCREENING GUIDELINES WERE ISSUED IN CHINA.
Chen Y; Feng J; Li F; Yin H; Liang J; Li X
Retina; 2015 Aug; 35(8):1674-9. PubMed ID: 25719989
[TBL] [Abstract][Full Text] [Related]
22. Treated Cases of Retinopathy of Prematurity in Germany: 10-Year Data from the Retina.net Retinopathy of Prematurity Registry.
Pfeil JM; Barth T; Lagrèze WA; Lorenz B; Hufendiek K; Liegl R; Breuss H; Bemme S; Aisenbrey S; Glitz B; Süsskind D; Gabel-Pfisterer A; Skevas C; Krohne TU; Kakkassery V; Bründer MC; Engelmann K; Guthoff R; Walter P; Choritz L; Stahl A;
Ophthalmol Retina; 2024 Jun; 8(6):579-589. PubMed ID: 38104929
[TBL] [Abstract][Full Text] [Related]
23. Treatment for retinopathy of prematurity in Sweden 2008-2021: Reduced gestational age of treated infants and remaining differences in treatment type and recurrence rates between hospitals.
Holmström G; Hellström A; Teär Fahnehjelm K; Gränse L; Sandgren Hochhard K; Sunnqvist B; Tornqvist K; Tsamadou D; Wallin A; Larsson E
Acta Ophthalmol; 2024 Jun; 102(4):401-408. PubMed ID: 37698061
[TBL] [Abstract][Full Text] [Related]
24. OUTCOMES OF NONCONFLUENT DIODE LASER PANRETINAL PHOTOCOAGULATION FOR AGGRESSIVE POSTERIOR RETINOPATHY OF PREMATURITY AFTER INTRAVITREAL BEVACIZUMAB.
Mammo DA; Rubino SM; Quiram PA
Retina; 2021 Apr; 41(4):706-710. PubMed ID: 32796444
[TBL] [Abstract][Full Text] [Related]
25. Preliminary anatomical and neurodevelopmental outcomes of intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity.
Araz-Ersan B; Kir N; Tuncer S; Aydinoglu-Candan O; Yildiz-Inec D; Akdogan B; Ekici B; Demirel A; Ozmen M
Curr Eye Res; 2015 May; 40(6):585-91. PubMed ID: 25025864
[TBL] [Abstract][Full Text] [Related]
26. Screening for retinopathy of prematurity in China: a neonatal units-based prospective study.
Xu Y; Zhou X; Zhang Q; Ji X; Zhang Q; Zhu J; Chen C; Zhao P
Invest Ophthalmol Vis Sci; 2013 Dec; 54(13):8229-36. PubMed ID: 24204053
[TBL] [Abstract][Full Text] [Related]
27. Screening for retinopathy of prematurity and treatment outcome in a tertiary hospital in Hong Kong.
Iu LP; Lai CH; Fan MC; Wong IY; Lai JS
Hong Kong Med J; 2017 Feb; 23(1):41-7. PubMed ID: 28035052
[TBL] [Abstract][Full Text] [Related]
28. Intravitreal bevacizumab following laser therapy for severe retinopathy of prematurity.
Erol N; Gürsoy H; Sahin A; Basmak H
J Pediatr Ophthalmol Strabismus; 2010 Aug; 47 Online():e1-4. PubMed ID: 21158371
[TBL] [Abstract][Full Text] [Related]
29. Outcomes of Intravitreal Bevacizumab and Diode Laser Photocoagulation for Treatment-Warranted Retinopathy of Prematurity.
Chen TA; Schachar IH; Moshfeghi DM
Ophthalmic Surg Lasers Imaging Retina; 2018 Feb; 49(2):126-131. PubMed ID: 29443362
[TBL] [Abstract][Full Text] [Related]
30. The prevalence of retinopathy of prematurity in very low birth weight newborn infants.
Lermann VL; Fortes Filho JB; Procianoy RS
J Pediatr (Rio J); 2006; 82(1):27-32. PubMed ID: 16532144
[TBL] [Abstract][Full Text] [Related]
31. Playing With Fire.
Harper CA; Beck KD; Chang E; Young R; Moshfeghi DM
Ophthalmic Surg Lasers Imaging Retina; 2020 Oct; 51(10):542-544. PubMed ID: 33104220
[TBL] [Abstract][Full Text] [Related]
32. OUTCOMES AFTER LASER VERSUS COMBINED LASER AND BEVACIZUMAB TREATMENT FOR TYPE 1 RETINOPATHY OF PREMATURITY IN ZONE I.
Yoon JM; Shin DH; Kim SJ; Ham DI; Kang SW; Chang YS; Park WS
Retina; 2017 Jan; 37(1):88-96. PubMed ID: 27347645
[TBL] [Abstract][Full Text] [Related]
33. Incidence of retinopathy of prematurity in extremely premature infants over an 18-year period.
Gunn DJ; Cartwright DW; Gole GA
Clin Exp Ophthalmol; 2012; 40(1):93-9. PubMed ID: 22044448
[TBL] [Abstract][Full Text] [Related]
34. Low dose versus conventional dose of intravitreal bevacizumab injection for retinopathy of prematurity: a case series with paired-eye comparison.
Han J; Kim SE; Lee SC; Lee CS
Acta Ophthalmol; 2018 Jun; 96(4):e475-e478. PubMed ID: 27011262
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of intravitreal bevacizumab for zone-II retinopathy of prematurity.
Karkhaneh R; Khodabande A; Riazi-Eafahani M; Roohipoor R; Ghassemi F; Imani M; Dastjani Farahani A; Ebrahimi Adib N; Torabi H
Acta Ophthalmol; 2016 Sep; 94(6):e417-20. PubMed ID: 27009449
[TBL] [Abstract][Full Text] [Related]
36. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.
Sankar MJ; Sankar J; Mehta M; Bhat V; Srinivasan R
Cochrane Database Syst Rev; 2016; 2():CD009734. PubMed ID: 26932750
[TBL] [Abstract][Full Text] [Related]
37. Incidence and result of treatment-demanding retinopathy of prematurity using revised U.S. screening guidelines.
Kuo HK; Chen CC; Chen YH; Huang HC; Liu CA; Chen FS; Chung MY
Am J Perinatol; 2012 Nov; 29(10):827-31. PubMed ID: 22773294
[TBL] [Abstract][Full Text] [Related]
38. Incidence of retinopathy of prematurity and risk factors among premature infants at a neonatal intensive care unit in Canada.
Isaza G; Arora S; Bal M; Chaudhary V
J Pediatr Ophthalmol Strabismus; 2013; 50(1):27-32. PubMed ID: 23205771
[TBL] [Abstract][Full Text] [Related]
39. Incidence of retinopathy of prematurity in a neonatal intensive care unit in Nepal.
Shrestha JB; Bajimaya S; Sharma A; Shresthal J; Karmacharya P
J Pediatr Ophthalmol Strabismus; 2010; 47(5):297-300. PubMed ID: 19928699
[TBL] [Abstract][Full Text] [Related]
40. Regression Rates Following the Treatment of Aggressive Posterior Retinopathy of Prematurity with Bevacizumab Versus Laser: 8-Year Retrospective Analysis.
Nicoară SD; Ștefănuţ AC; Nascutzy C; Zaharie GC; Toader LE; Drugan TC
Med Sci Monit; 2016 Apr; 22():1192-209. PubMed ID: 27062023
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
